Using our novel R&D platform for the advancement of life-changing medicines, we focus on neurological and endocrine based diseases and disorders.Learn More
We are developing a first-in-class, oral treatment option that addresses the chronic, intermittent, predictable and unpredictable symptoms common to Endometriosis and Uterine Fibroids.
We are developing the first therapy for the treatment of unwanted movements to improve the quality of life for those affected by schizophrenia and bipolar disease.
We are developing a convenient, once-daily treatment for tics that allows patients, caregivers, and physicians the ability to take charge of the disease and manage symptoms on their own terms.
We are developing a non-steroidal therapy for Classical CAH to treat the effects of life-long elevated androgens and the use of high-dose corticosteroids both of which can lead to the virilization of females, metabolic syndrome, bone loss, growth impairment, and Cushing's syndrome.